BioSpace News Archive

Biomea Fusion, Inc. announced three poster presentations presenting long-term 26 week follow-up data from patients treated with BMF-219, enrolled in the escalation portion of the ongoing Phase II clinical study, at the 17th International Conference on Advanced Technologies & Treatments for Diabetes taking place in Florence, Italy from March 6-9, 2024.

Royal Philips, a global leader in health technology, has been included in the 2024 Clarivate Top 100 Global Innovator™ list.

In 2023, the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research approved 55 new drugs, 17 of which were biopharmaceuticals.

Ryvu Therapeutics announced that preclinical data from its synthetic lethality pipeline and RVU120 project, as well as on MEN1703, will be presented at the upcoming 2024 AACR Annual Meeting, scheduled for April 5-10 in San Diego, California.

Medigene AG will present a poster at the American Association for Cancer Research Annual Meeting 2024 taking place from April 5-10, 2024 in San Diego, USA as well as an oral presentation at the ELRIG-Forum 2024 to be held in Darmstadt, Germany on March 7, 2024.

Akeso Inc. announced the enrollment of the first patient in the registrational Phase III clinical study comparing Cadonilimab combined with chemotherapy versus Tislelizumab combined with chemotherapy in the first-line treatment for patients with PD-L1 negative non-small cell lung cancer.

BeiGene, Ltd., a global oncology company, announced the presentation of emerging oncology pipeline data at the American Association for Cancer Research Annual Meeting April 5-10 in San Diego.

Gradient Denervation Technologies announced that the Food and Drug Administration has approved the initiation of the PreVail-PH2 Early Feasibility Study in the United States.

Affimed N.V. announced that the Company, with prior approval of the Company’s supervisory board and management board, intends to effect a 1-for-10 reverse stock split of its outstanding common shares, par value €0.01 per share.

Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies’ long-term development.